The Novo and Immunocore-backed cancer treatment developer has targeted $150m from a Nasdaq IPO, filing seven months after a $104m series A round.

Corporate-backed cardiovascular imaging technology developer Infraredx has withdrawn a $55m initial public offering it filed for in December 2014.

The cell engineering technology company has also inked a joint research agreement with a Novartis subsidiary.

The cell engineering technology company has also inked a joint research agreement with a Novartis subsidiary.

Nabriva, which is developing antibiotics for drug-resistant infections, has now raised more than $190m in total and will advance its lead candidate into Phase 3 studies.

Johnson & Johnson has provided the first healthcare venture group investment in the Vivo Capital Fund VIII that aims to help US and Chinese businesses work cross-border.

Qualcomm Ventures has reinvested in Noom, a health app developer that is using human and artificial intelligence interaction to drive behaviour change in people with chronic illnesses or those wanting to lose weight.